计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| O612552-1mg |
1mg |
现货 ![]() |
| |
| O612552-5mg |
5mg |
现货 ![]() |
| |
| O612552-10mg |
10mg |
现货 ![]() |
| |
| O612552-25mg |
25mg |
现货 ![]() |
| |
| O612552-50mg |
50mg |
现货 ![]() |
| |
| O612552-100mg |
100mg |
现货 ![]() |
|
| 别名 | 奥利万星 |
|---|---|
| 英文别名 | CHEBI:82699 | Chlorobiphenyl-chloroeremomycin | Q7102878 | LY 333328 | UNII-PUG62FRZ2E | (4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin | NCGC00485478-01 | NCGC00485478-02 | ORI |
| 规格或纯度 | Moligand™, ≥80%, 以无水计 |
| 英文名称 | Oritavancin diphosphate |
| 生化机理 | Oritavancin diphosphate (LY333328 diphosphate) 是 Vancomycin (HY-B0671) 的半合成衍生物,是具有口服活性的糖肽抗生素 (antibiotic),对革兰氏阳性菌具有杀菌 (bactericidal) 活性。Oritavancin diphosphate 对 B. anthracis 有抗菌 (antibacterial) 作用,如 Ames 菌株,其 MIC 值为 0.015 g/mL。Oritavancin diphosphate 抑制细胞壁合成和破坏膜电位。Oritavancin diphosphate 抑制 ArlS 激酶活性从而干扰信号转导。Oritavancin diphosphate 通过吸附内吞作用进入细胞,将其驱动到溶酶体,在那里发挥抗生素 (antibiotic) 活性。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Oritavancin diphosphate (LY333328 diphosphate) 是一种新型半合成的糖肽抗生素, 可研究革兰氏阳性菌感染。
Oritavancin diphosphate (LY333328 diphosphate) is a novel semisynthetic glycopeptide antibiotic developed for treating serious Gram-positive bacterial infections.
|
| 纯度 | ≥80% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 未知 |
|---|---|
| IIUPAC Name | (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid |
| INCHI | 1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1 |
| InChi Key | PWTROOMOPLCZHB-BHYQHFGMSA-N |
| Smiles | CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O |
| Isomeric SMILES | C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O |
| 分子量 | 1989.09 |
| 溶解性 | DMSO: 14 mg/mL (7.04 mM) |
|---|---|
| 敏感性 | 对湿度敏感 |
| 分子量 | 1793.100 g/mol |
| XLogP3 | 1.500 |
| 氢键供体数Hydrogen Bond Donor Count | 20 |
| 氢键受体数Hydrogen Bond Acceptor Count | 29 |
| 可旋转键计数Rotatable Bond Count | 19 |
| 精确质量Exact Mass | 1790.56 Da |
| 单同位素质量Monoisotopic Mass | 1790.56 Da |
| 拓扑极表面积Topological Polar Surface Area | 561.000 Ų |
| 重原子数Heavy Atom Count | 125 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 3700.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 22 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| RIDADR | NONHforallmodesoftransport |
|---|
¥2,999.90
| 1. Arhin FF, Draghi DC, Pillar CM, Parr Jr TR, Moeck G, Sahm DF. (2009) Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.. Antimicrob Agents Chemother, 53 (11): (4762-71). [PMID:19738026] |
| 2. Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W, SOLO I and SOLO II investigators. (2018) Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.. Antimicrob Agents Chemother, 62 (4): [PMID:29358292] |
| 3. Yechang Guo, Shaofeng Wang, Peiyue Li, Pan Zhang, Wei Wang. (2023) Rapid Colloidal Gold Immunoassay for Pharmacokinetic Evaluation of Vancomycin in the Cerebrospinal Fluid and Plasma of Beagle Dogs. SENSORS, 23 (21): (8978). [PMID:37960677] [10.3390/s23218978] |